ArticleAnalytical chemistry2025
ATR-FTIR Spectroscopy of Saliva and Machine Learning as a Screening Test for Sjögren Disease.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's disease is often an underdiagnosed autoimmune condition that primarily affects the exocrine glands, resulting in symptoms such as dry eyes and dry mouth. Diagnostic challenges stem from nonspecific symptoms, the absence of definitive biomarkers, and the invasiveness and cost associated with current clinical tests. This study investigates the application of attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR), in conjunction with a neural network and Monte Carlo dropout-based uncertainty estimation to distinguish patients with Sjögren's disease from healthy individuals. Uncertainty estimates were used to identify ambiguous spectra and refine training data, improving predictive performance and enabling confidence-aware interpretation. To minimize bias related to sex-based prevalence, model training was limited to female participants, among whom the disease is more common. To guarantee independent validation, a stratified cross-validation strategy was used. In each fold, the network is initialized with random weights, trained exclusively on the training subset, and evaluated on the corresponding unseen data. The refined (uncertainty-aware) model achieved 75% accuracy and 73% sensitivity at the individual spectrum level, and 79% accuracy and 76% sensitivity at the patient level. These findings highlight the potential of an uncertainty-aware, noninvasive, machine learning-based method as a reliable tool for the early diagnosis of Sjögren's Disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.